Payment overview · 2025
General Payments
$1,480.52
82 reported records · 14 companies
Healthcare provider profile · identity verified
John Preston Lilly, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DUNBAR, WV · NPI 1144281585
Verified facts
What the public records show
CMS Open Payments records show John Preston Lilly, MD received $1,480.52 in general payments during 2025 across 82 reported records.
Novo Nordisk Inc accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $419.50 | 28.3% | 24 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $234.12 | 15.8% | 16 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $203.04 | 13.7% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $189.68 | 12.8% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $155.28 | 10.5% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $63.12 | 4.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $54.35 | 3.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.83 | 2.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.67 | 2.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.57 | 1.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.60 | 1.3% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $19.58 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.96 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.22 | 1.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,480.52 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $356.37 | 21 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $315.15 | 19 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $203.04 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $185.73 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $185.73 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $155.28 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $112.58 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $82.72 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $75.93 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.13 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $54.35 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.80 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $31.90 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.83 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.67 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.57 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.22 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 764 | 254 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 610 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 594 | 184 |
| Gabapentin | Gabapentin | 500 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 141 |
| Alprazolam | Alprazolam | 468 | 109 |
| Losartan Potassium | Losartan Potassium | 400 | 140 |
| Metoprolol Succinate | Metoprolol Succinate | 390 | 132 |
| Lisinopril | Lisinopril | 339 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 320 | 112 |
| Metformin Hcl | Metformin Hcl | 282 | 86 |
| Tramadol Hcl | Tramadol Hcl | 270 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 70 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 225 | 44 |
| Potassium Chloride | Potassium Chloride | 217 | 77 |
| Furosemide | Furosemide | 216 | 86 |
| Lorazepam | Lorazepam | 208 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 203 | 62 |
| Omeprazole | Omeprazole | 192 | 63 |
| Montelukast Sodium | Montelukast Sodium | 186 | 59 |
| Trazodone Hcl | Trazodone Hcl | 172 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 59 |
| Simvastatin | Simvastatin | 166 | 54 |
| Clonazepam | Clonazepam | 165 | 36 |
| Valsartan | Valsartan | 165 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 59 |
| Glimepiride | Glimepiride | 125 | 40 |
| Jardiance | Empagliflozin | 121 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 117 | 23 |
| Ozempic | Semaglutide | 117 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 112 | 33 |
| Famotidine | Famotidine | 111 | 43 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 110 | 35 |
| Celecoxib | Celecoxib | 108 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 108 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 39 |
| Sulindac | Sulindac | 104 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 35 |
| Allopurinol | Allopurinol | 98 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 28 |
| Finasteride | Finasteride | 87 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 31 |
| Prednisone | Prednisone | 87 | 65 |
| Warfarin Sodium | Warfarin Sodium | 87 | 19 |
| Donepezil Hcl | Donepezil Hcl | 85 | 22 |
| Atenolol | Atenolol | 84 | 29 |
| Buspirone Hcl | Buspirone Hcl | 84 | 26 |
| Xarelto | Rivaroxaban | 84 | 19 |
| Carvedilol | Carvedilol | 83 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 42 |
| Eliquis | Apixaban | 79 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 32 |
| Azithromycin | Azithromycin | 73 | 62 |
| Cephalexin | Cephalexin | 71 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 28 |
| Sertraline Hcl | Sertraline Hcl | 70 | 26 |
| Bupropion Xl | Bupropion Hcl | 69 | 28 |
| Synthroid | Levothyroxine Sodium | 62 | 18 |
| Pregabalin | Pregabalin | 59 | 25 |
| Temazepam | Temazepam | 59 | 14 |
| Spironolactone | Spironolactone | 58 | 23 |
| Nabumetone | Nabumetone | 57 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 17 |
| Diazepam | Diazepam | 48 | 18 |
| Farxiga | Dapagliflozin Propanediol | 48 | 14 |
| Glipizide | Glipizide | 48 | 12 |
| Meloxicam | Meloxicam | 48 | 16 |
| Meclizine Hcl | Meclizine Hcl | 47 | 24 |
| Alendronate Sodium | Alendronate Sodium | 45 | 14 |
| Clonidine Hcl | Clonidine Hcl | 43 | 17 |
| Methylprednisolone | Methylprednisolone | 43 | 40 |
| Ezetimibe | Ezetimibe | 40 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 14 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 39 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 14 |
| Fluocinonide | Fluocinonide | 36 | 22 |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Ondansetron Odt | Ondansetron | 34 | 13 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Carisoprodol | Carisoprodol | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Naproxen | Naproxen | 29 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | 11 |
| Torsemide | Torsemide | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 20 |
| Irbesartan | Irbesartan | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | 11 |
| Risperidone | Risperidone | 17 | 12 |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,480.52 · 82 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, Kerendia, LINZESS, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VIBERZI, VOQUEZNA, VYNDAMAX, Wegovy, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error